



Review Article

Mesenchymal stem cells for articular cartilage repair treatment of the knee. A review of clinical studies

Christos P. Margiannis¹, Stylianos S. Pernientakis², Ioannis F. Mamais³, Efstathios G. Ballas¹

¹Paediatric Orthopedics Department, "Mitera" General Private Hospital, Athens, Greece

²Orthopaedic Department, "Korgialeneio Mpenakeio Hellenic Red Cross" Athens General Hospital, Greece

³Orthopaedic Department, "Iatriko Palaίου Falirou" Private Hospital, Greece

Abstract

Knee cartilage lesions are a common source of pain and progressive debilitation affecting individuals in all age groups. Treatment of these lesions remains a challenge due to the poor healing capacity of the articular cartilage. Numerous techniques with various improvements in terms of pain and function have been published and only few of them have been proven to be valuable. Mesenchymal stem cells provide a new option for treatment due to their differentiation properties into several connective tissues. They can be isolated from several human tissues such as bone marrow, adipose tissue, synovial tissue, peripheral blood and periosteum. When applied in combination with proper biomaterials used as scaffolds as well as growth and other stimuli factors, they represent a promising treatment strategy. Aim of our study is to review the clinical trials which evaluate the current status of MSCs application for the management of knee cartilage lesions.

Keywords: Articular cartilage, Knee, Mesenchymal stem cells

Introduction

Knee cartilage lesions are common injuries and can affect patients of all age groups. One review of 31,516 knee arthroscopies, found that 63% of patients had chondral lesions with most of patients aged less than 40 years, presenting with a solitary lesion¹. They result in severe pain and loss of function of the affected knee and are associated with the development of osteoarthritis in the long term². The problem with these lesions is that despite conservative and surgical methods applied, they remain highly irreversible and only inferior repair is possible. Fibrous repair tissue is formed, (fibrocartilage) which is not characterized by the same biomechanical properties as hyaline cartilage. It is susceptible to failure under high compressive forces during knee movements, deteriorates over time and can lead to the previous symptoms experienced by the patient³.

While conservative treatment of these lesions remains unchanged over time, there is a wide variety of options available once surgical intervention is decided. These include cartilage repair with osteochondral autograft transfer, microfracture, autologous chondrocyte implantation (ACI), matrix induced ACI, use of growth factors, platelet rich plasma, bone morphogenetic proteins, magnetically labeled synovium derived cells M-SDCs and chondroprotection

with pulsed electromagnetic fields⁴⁻¹². However, there is increasing evidence in the literature and an emerging focus on the management of these lesions with the use of mesenchymal stem cells. It seems that their unique characteristics may give them an advantage compared to other treatment modalities.

Mesenchymal stem cells (MSCs) have been first reported in bone marrow in 1966 and took their name in the early 90s¹³. MSCs are undifferentiated cells which can differentiate into cartilage, fat, bone, ligament, marrow stroma etc¹⁴. Therefore, all these tissues consist potential sources of MSCs. They have self-renewal capacity, plasticity and most importantly can suppress the immune system

The authors have no conflict of interest.

Corresponding author: Christos P. Margiannis, Aghias Lavras 49, Zografou, Athens, 15773 Greece

E-mail: margiannis-christos@hotmail.com

Edited by: Konstantinos Stathopoulos

Accepted 1 December 2020

through various mechanisms such as suppression of natural killer(NK) cell activation and inhibition of T and L lymphocyte activation¹⁵.

Their first application for osteochondral defect treatment was performed in rabbits with their first use in humans reported in 2001 by Quarto et al.^{16,17}. Bone marrow derived stem cells use has been reported in animal and human research studies^{18,19}. Bone marrow has a high MSC density and these cells seem to favor differentiation of deep articular cartilage zone close to healthy bone²⁰. Synovium is another great source of MSCs with chondrogenesis potential, while peripheral blood is characterized by low MSC density, difficulty during cell isolation and poor results²¹. MSCs are mostly injected in the affected knee or applied with the use of scaffold implantation combined with growth or transcription factors like TGF- β , BMP-7, hyaluronic acid and others^{22,23}.

Our focus in this study was to provide a short review of the available evidence concerning the use of MSCs for articular cartilage repair treatment of the knee in humans.

Materials and methods

We searched pubmed studies focused on articular repair treatment of the knee with the use of mesenchymal stem cells. The keywords we searched were the following: cartilage, bone marrow-derived MSCs, articular cartilage repair, mesenchymal stem cells, synovial-derived MSCs, adipose-derived MSCs knee, articular regeneration. Our search included only articles in English language of the last 10 years.

Results

Along with the advantage of the ease of collection of the cells, bone marrow-derived MSCs (BMSCs) are mostly used in the studies identified²⁴. BMSCs can be used as cultured cells or as a bone marrow concentrate (BMC)^{25,26}. BMC offers the advantage of a greater number of progenitor cells but a lower number of MSCs compared to cultured cells²⁷. Additionally, cultured amplification of MSCs has several limitations. Except for the fact that it can be considered as a pharmaceutical administration, thus raising ethical issues, the risk of bacterial contamination, hypertrophy of the cells and cellular transformation cannot be overlooked^{28,29}.

To modify progenitor cells, viral vectors are commonly used. Recombinant adeno-associated viruses (rAAV) are characterized by lower toxicity and oncogene activation compared to other adenoviral and retroviral vectors and are widely used³⁰.

Most studies involving the use of bone marrow-derived mesenchymal stem cells (BMSCs) in the human knee are case series studies and case reports. In their comparative study in 24 patients with knee osteoarthritis and medial femoral condyle cartilage lesions, Wakitani et al. used cultured BMSCs in a type I collagen gel scaffold and a periosteal flap. Their control group of 12 patients received no cells in the scaffold. At 16 months follow-up, although no clear clinical

result was shown between the two groups, the histological and arthroscopic grading score was better in the MSC group than in the cell-free control group³¹. In 2004, the same group reported on two individuals with full thickness patellar lesion. The same technique was used, leading to satisfactory results for both patients in terms of pain and function and clinical improvement lasted for 4 and 5 years respectively³². Three more patients with a total of nine full thickness patellofemoral cartilage defects have been treated from the same group with the above technique, reporting significant improvement at follow-up (17-27 months) with additional complete coverage of the defect on MRI and histology signs of repair³³.

Haleem et al. placed BMSCs on platelet-rich fibrin glue in the operating theatre and then covered them with an autologous periosteal flap to deal with full thickness articular cartilage lesions of the femoral condyle in 5 patients. After 6 and 12 months, all patients presented with reduced pain and better functional outcomes. Two patients were treated arthroscopically at 1 year follow-up and showed ICRS scores close to normal. MRI of five patients was evaluated 12 months post-transplantation with 3 of them revealing complete surface congruity and defect coverage and 2 incomplete congruity despite the satisfactory clinical result³⁴.

A recent cohort study compared autologous chondrocyte implantation (ACI) with BMSC treatment for the management of these knee lesions in 72 age and lesion matched patients. Patients were followed for 3, 6, 9, 12, 18 and 24 months after the operation. All patients showed significant clinical improvement with men showing a greater benefit from surgery. Interestingly, patients, less than 45 years old scored better when ACI was chosen. Authors came to the conclusion that BMSCs can have similar effect as ACI for the treatment of knee cartilage lesions while offering the advantage of a single lower cost knee operation with limited donor-site morbidity³⁵.

Satisfactory cartilage regeneration was also noted in case reports when cultured BMSCs on hydroxyapatite ceramic or collagen scaffold alone was used^{36,37}.

Injection techniques of cultured BMSCs have also been studied for the treatment of cartilage knee lesions. Emadedin et al. reported on six patients with osteoarthritis of the knee joint who underwent an injection of cultured BMSCs. Up to six months post-injection, there was a clear improvement in terms of pain, function and walking distance with MRI findings revealing an increase in cartilage thickness³⁸. Satisfactory outcome was shown by Davatchi et al. with the use of the same technique³⁹.

Bone marrow concentrate (BMC) has also been used in knee cartilage defects instead of BMSCs. However, there is little evidence to support its use. In a comparative study of 50 patients, half of them underwent arthroscopic debridement for knee OA and the rest BMC injection along with debridement for the same disease. It was reported that patients on the injection group had better visual analogue

scale and osteoarthritis outcome scores and better quality of life than the debridement alone group⁴⁰. Buda et al. implanted BMC on hyaluronic acid membrane and platelet rich fibrin in 20 patients with knee osteochondral defects with an arthroscopic technique. At 24 months, clear clinical improvement along with cartilage repair and subchondral bone regeneration was observed⁴¹. Finally, a case series of 5 patients with medial femoral condyle lesions who were treated with arthroscopic autologous matrix-induced chondrogenesis (AMIC) augmented with BMC revealed nearly normal arthroscopic appearance on second look arthroscopy at 12 months follow-up. Moreover in 4 out of 5 patients a mixture of hyaline/fibrocartilage was identified histologically⁴².

Synovial-derived MSCs have also been reported as an alternative source of cells for cartilage repair. Unfortunately from our search, no clinical study in humans was identified. On the other hand, we identified two clinical studies using adipose-derived MSCs (ADMSCs) for the management of knee osteoarthritis. In a case series study, two Korean women with knee osteoarthritis were treated with ADMSCs along with PRP, hyaluronic acid, calcium chloride and 1mg of dexamethasone injections. At three months follow-up, the authors report an increase in cartilage thickness on MRI with clear improvements in pain score and functional properties⁴³. Additionally, Koh et al. reported on a comparative study where two different groups of patients were examined. The study group of 25 individuals received infrapatellar fat pad derived MSCs along with arthroscopic debridement for knee osteoarthritis. The control group was treated with debridement and PRP injections alone. Although the study group patients had poorer knee and pain scores preoperatively, clinical results were reported to be similar at the latest follow-up exam, 16 months after surgery⁴⁴.

No clinical studies involving periosteum derived MSCs are available to date for the management of knee cartilage lesions.

Discussion

Stem cells are matured from cells of the germ layer. Mesenchymal stem cells (MSCs) can be derived from tissues such as bone marrow, synovial tissue fat and periosteum⁴⁵. There is emerging evidence in the literature concerning the use of mesenchymal stem cells for the treatment of osteochondral lesions of the knee. However, most of the studies are conducted in animals and few of the advances presented preclinically have also been applied in the clinical practice⁴⁶⁻⁴⁸. Additionally, low quality clinical studies are available, mostly due to problems with methodology, few patients and not adequate follow up period. Thus, there is still room for quality scientific research in this topic and many aspects of their use have not yet been clarified.

The optimal source of mesenchymal stem cells is still under debate with its type having its advantages and drawbacks. For example, preclinical data show that adipose-derived MSCs have the best potential for adipogenesis,

synovial-derived MSCs may be a valuable option for regeneration of the chondral tissue and bone marrow and periosteum derived cells are superior for osteogenesis^{49,50}. Recently, Koga et al. showed that synovial and bone marrow derived MSCs are superior to adipose and muscle-derived ones for full thickness articular cartilage lesions⁵¹.

Moreover, it is yet to be determined whether these cells should be cultured or concentrated, which is the appropriate quantity of cells that should be used, which is the best technique for implantation, open or minimally invasive as well as which biological factor or scaffold should be used for the best possible result.

Except for all these unanswered questions, other aspects that should be determined include the potential risks of MSCs use. Researchers must be able to control hypertrophic differentiation of the cells as well as differentiation in unwanted tissue such as endochondral ossification in some parts of cartilage repair tissue⁵². Controversy exists in the literature concerning the safety of the use of MSCs with studies reporting no side effects even in the long term and others raising concerns about the possible transformation of the cells while they have been cultured^{53,54}. In any case, their effectiveness and overall safety is not yet convincingly proven leaving a cause for concern. Long term, multicenter, double-blind randomized control studies will help us understand the biological pathway of these cells and provide sufficient evidence to clarify all the above controversial issues. The fact is that regeneration of natural articular cartilage has not yet been reported. The challenge of the upcoming years will be to try to assemble all these different and complicated aspects in order to put into clinical practice an effective and most importantly safe technique.

Conclusion

Our study tried to summarize current data from clinical studies available reporting on the treatment of knee cartilage lesions with mesenchymal stem cells. Despite growing interest on this subject, low quality studies with small number of patients are mostly available. Until long term randomized controlled multicenter studies are available to provide definite conclusions, the use of these cells, derived from different human tissues, will be a great area for scientific research and controversy.

References

1. Curl WW, Krome J, Gordon ES, Rushing J, Smith BP, Poehling GG. Cartilage injuries: a review of 31,516 knee arthroscopies. *Arthroscopy* 1997;13(4):456-460.
2. D'Anchise R, Manta N, Prospero E, Bevilacqua C, Gigante A. Autologous implantation of chondrocytes on a solid collagen scaffold: clinical and histological outcomes after two years of follow-up. *J Orthop Traumatol* 2005; 6:36-43.
3. Craig W, David JW, Ming HZ. A current review on the biology and treatment of the articular cartilage defects (part I & part II). *J Musculoskelet Res* 2003;7(3&4):157-181.

4. Bae DK, Yoon KH, Song SJ. Cartilage healing after microfracture in osteoarthritic knees. *Arthroscopy* 2006; 22(4):367–374.
5. Anders S, Schaumburger J, Schubert T, Grifka J, Behrens P. Matrix-associated autologous chondrocyte transplantation (MACT). Minimally invasive technique in the knee. *Oper Orthop Traumatol* 2008;20(3):208–219.
6. Magnussen RA, Dunn WR, Carey JL, Spindler KP. Treatment of focal articular cartilage defects in the knee: a systematic review. *Clin Orthop Relat Res* 2008;466(4):952–96.
7. Gigante A, Enea D, Greco F, Bait C, Denti M, Schonhuber H, et al. Distal realignment and patellar autologous chondrocyte implantation: mid-term results in a selected population. *Knee Surg Sports Traumatol Arthrosc* 2009;17(1):2–10.
8. Kon E, Buda R, Filardo G, Di Martino A, Timoncini A, Cenacchi A, et al. Platelet-rich plasma: intra-articular knee injections produced favorable results on degenerative cartilage lesions. *Knee Surg Sports Traumatol Arthrosc* 2010;18(4):472–479.
9. Noh MJ, Copeland RO, Yi Y, Choi KB, Meschter C, Hwang S, et al. Pre-clinical studies of retrovirally transduced human chondrocytes expressing transforming growth factor-beta-1 (TG-C). *Cytotherapy* 2010;12(3):384–393.
10. Schmal H, Niemeyer P, Zwingmann J, Stoffel F, Sudkamp NP, Mehlhorn AT. Association between expression of the bone morphogenetic proteins 2 and 7 in the repair of circumscribed cartilage lesions with clinical outcome. *BMC Musculoskelet Disord* 2010;11:170.
11. Hori J, Deie M, Kobayashi T, Yasunaga Y, Kawamata S, Ochi M. Articular cartilage repair using an intra-articular magnet and synovium-derived cells. *J Orthop Res* 2011;29(4):531–538.
12. Zorzi C, Dall'Oca C, Cadossi R, Setti S. Effects of pulsed electromagnetic fields on patients' recovery after arthroscopic surgery: prospective, randomized and double-blind study. *Knee Surg Sports Traumatol Arthrosc* 2007;15(7):830–834.
13. Spencer ND, Gimble JM, Lopez MJ. Mesenchymal stromal cells: past, present, and future. *Vet Surg* 2011;40(2):129–139.
14. Lodi D, Iannitti T, Palmieri B. Stem cells in clinical practice: applications and warnings. *J Exp Clin Cancer Res* 2011;30:9.
15. Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation. *Annu Rev Pathol* 2011;6:457–478.
16. Quarto R, Mastrogiacomo M, Cancedda R, Kutepov SM, Mukhachev V, Lavroukov A et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. *N Engl J Med* 2001;344(5):385–386.
17. Wakitani S, Goto T, Pineda SJ, Young RG, Mansour JM, Caplan AI, et al. Mesenchymal cell-based repair of large, full-thickness defects of articular cartilage. *J Bone Joint Surg Am* 1994;76(4):579–592.
18. Huang JI, Kazmi N, Durbhaskula MM, Hering TM, Yoo JU, Johnstone B. Chondrogenic potential of progenitor cells derived from human bone marrow and adipose tissue: a patient- matched comparison. *J Orthop Res* 2005;23(6):1383–1389.
19. Chen J, Wang C, Lu S, Wu J, Guo X, Duan C, et al. In vivo chondrogenesis of adult bonemarrow- derived autologous mesenchymal stem cells. *Cell Tissue Res* 2005;319(3):429–438.
20. Steck E, Fischer J, Lorenz H, Gotterbarm T, Jung M, Richter W. Mesenchymal stem cell differentiation in an experimental cartilage defect: restriction of hypertrophy to bone-close neocartilage. *Stem Cells Dev* 2009;18(7):969–978.
21. Saw KY, Anz A, Merican S, Tay YG, Ragavanaidu K, Jee CS, et al. Articular cartilage regeneration with autologous peripheral blood progenitor cells and hyaluronic acid after arthroscopic subchondral drilling: a report of 5 cases with histology. *Arthroscopy* 2011;27(4):493–506.
22. Mokbel AN, El Tookhy OS, Shamaa AA, Rashed LA, Sabry D, El Sayed AM. Homing and reparative effect of intraarticular injection of autologous mesenchymal stem cells in osteoarthritic animal model. *BMC Musculoskelet Disord* 2011;15:12:259.
23. Kim HJ, Im GI. Chondrogenic differentiation of adipose tissue-derived mesenchymal stem cells: greater doses of growth factor are necessary. *J Orthop Res* 2009;27(5):612–619.
24. Mosna F, Sensebe L, Krampera M. Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide. *Stem Cells Dev* 2010;19(10):1449–1470.
25. Gobbi A, Karnatzikos G, Scotti C, Mahajan V, Mazzucco L, Grigolo B. One-step cartilage repair with bone marrow aspirate concentrated cells and collagen matrix in full-thickness knee cartilage lesions: results at 2 year follow up. *Cartilage* 2011;2(3):286–299.
26. Krampera M, Pizzolo G, Aprili G, Franchini M. Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. *Bone* 2006;39(4):678–683.
27. Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D. Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells. *Pain Physician* 2008;11(3):343–353.
28. Mueller MB, Tuan RS. Functional characterization of hypertrophy in chondrogenesis of human mesenchymal stem cells. *Arthritis Rheum* 2008 58(5):1377–1388.
29. Sensebe L, Krampera M, Schrezenmeier H, Bourin P, Giordano R. Mesenchymal stem cells for clinical application. *Vox Sang* 2010;98(2):93–107.
30. Cucchiari M, Madry H. Gene therapy for cartilage defects. *J Gene Med* 2005;7(12):1495–1509.
31. Wakitani S, Imoto K, Yamamoto T, Saito M et al. Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritic knees. *Osteoarthritis Cartilage* 2002;10(3):199–206.
32. Wakitani S, Mitsuoka T, Nakamura N, Toritsuka, Nakamura Y, Horibe S. Autologous bone marrow stromal cell transplantation for repair of full-thickness articular cartilage defects in human patellae: two case reports. *Cell Transplant* 2004;13(5):595–600.
33. Wakitani S, Nawata M, Tensho K, Okabe T, Machida H, Ohgushi H. Repair of articular cartilage defects in the patellofemoral joint with autologous bone marrow mesenchymal cell transplantation: three case reports involving nine defects in five knees. *J Tissue Eng Regen Med* 2007;1(1):74–79.
34. Haleem AM, Singergy AA, Sabry D, Atta HM, Rached LA, Chu CR, et al. The clinical use of human culture-expanded autologous bone marrow mesenchymal stem cells transplanted on platelet-rich fibrin glue in the treatment of articular cartilage defects: a pilot study and preliminary results. *Cartilage* 2010;1(4):253–261.
35. Nejadnik H, Hui JH, Feng Choong EP, Tai BC, Lee EH. Autologous bone marrow-derived mesenchymal stem cells versus autologous chondrocyte implantation: an observational cohort study. *Am J Sports Med* 2010;38(6):1110–1116.
36. Adachi N, Ochi M, Deie M, Ito Y. Transplant of mesenchymal stem cells and hydroxyapatite ceramics to treat severe osteochondral damage after septic arthritis of the knee. *J Rheumatol* 2005; 32(8):1615–1618.
37. Kasemkijwattana C, Hongeng S, Kesprayura S, Rungsinaporn V, Chaipinyo K, Chansiri K. Autologous bone marrow mesenchymal stem cells implantation for cartilage defects: two cases report. *J Med Assoc Thai* 2011;94(3):395–400.
38. Emadedin M, Aghdami N, Taghiyar L, Fazeli R, Moghadasali R, Jahangir S, et al. Intraarticular injection of autologous mesenchymal stem cells in six patients with knee osteoarthritis. *Arch Iran Med*

- 2012;15(7):422–428.
39. Davatchi F, Abdollahi BS, Mohyeddin M, Shahram F, Nikbin B. Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. *Int J Rheum Dis* 2011;14(2):211–215.
 40. Varma HS, Dadarya B, Vidyarthi A. The new avenues in the management of osteoarthritis of knee-stem cells. *J Indian Med Assoc* 2010;108(9):583–585.
 41. Buda R, Vannini F, Cavallo M, Grigolo B, Cenacchi A, Giannini S. Osteochondral lesions of the knee: a new one-step repair technique with bone-marrow-derived cells. *J Bone Joint Surg Am* 2010;92(2):2–11.
 42. Gigante A, Calcagno S, Cecconi S, Ramazzotti D, Manzotti S, Enea D. Use of collagen scaffold and autologous bone marrow concentrate as a one-step cartilage repair in the knee: histological results of second-look biopsies at 1 year follow-up. *Int J Immunopathol Pharmacol* 2011;24(1 Suppl 2):69–72.
 43. Pak J. Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose-tissue-derived stem cells: a case series. *J Med Case Rep* 2011;5:296.
 44. Koh YG, Choi YJ. Infrapatellar fat pad-derived mesenchymal stem cell therapy for knee osteoarthritis. *Knee* 2012;19(6):902–7.
 45. Anz AW, Hackel JG, Nilssen EC, Andrews JR. Application of biologics in the treatment of the rotator cuff, meniscus, cartilage, and osteoarthritis. *J Am Acad Orthop Surg* 2014;22(2):68–79.
 46. Dragoo JL, Carlson G, McCormick F, Khan-Farooqi H, Zhu M, Zuk PA, et al. Healing full-thickness cartilage defects using adipose-derived stem cells. *Tissue Eng* 2007;13(7):1615–1621.
 47. McIlwraith CW, Frisbie DD, Rodkey WG, Kisiday JD, Werpy NM, Kawcak CE, et al. Evaluation of intraarticular mesenchymal stem cells to augment healing of microfractured chondral defects. *Arthroscopy* 2011;27(11):1552–1561.
 48. Zschamack M, Hepp P, Richter R, Aigner T, Schulz R, Somerson J, et al. Repair of chronic osteochondral defects using predifferentiated mesenchymal stem cells in an ovine model. *Am J Sports Med* 2010;38(9):1857–1869.
 49. Chen FH. Mesenchymal stem cells in arthritic diseases. *Arthr Res Ther* 2008;10(5):223.
 50. Sakaguchi Y, Sekiya I, Yagishita K, Muneta T. Comparison of human stem cells derived from various mesenchymal tissues. Superiority of synovium as a cell source. *Arthritis Rheum* 2005;52(8):2521–2529.
 51. Koga H, Muneta T, Nagase T, Nimura A, Ju YJ, Mochizuki T, et al. Comparison of mesenchymal tissues-derived stem cells for in vivo chondrogenesis: suitable conditions for cell therapy of cartilage defects in rabbit. *Cell Tissue Res* 2008;333(2):207–215.
 52. Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM, et al. Potential risks of bone marrow cell transplantation into infarcted hearts. *Blood* 2007;110(4):1362–1369.
 53. Wakitani S, Okabe T, Horibe S, Mitsuoka T, Saito M, Koyama T, et al. Safety of autologous bone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. *J Tissue Eng Regen Med* 2011;5(2):146–150.
 54. Rubio D, Garcia-Castro J, Martin MC, de la Fuente R, Cigudosa JC, Lloyd AC, et al. Spontaneous human adult stem cell transformation. *Cancer Res* 2005;65(8):3035–3039.